Entering text into the input field will update the search result below

Alnylam, Novartis team up to explore targeted therapy to restore liver function

Hepatitis virus with human liver

Rasi Bhadramani/iStock via Getty Images

  • Alnylam Pharmaceuticals (NASDAQ:ALNY) announces a collaboration with Novartis (NYSE:NVS) to leverage its proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.